Detalhe da pesquisa
1.
Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory.
Nat Immunol
; 22(8): 1030-1041, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34312544
2.
Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection.
Immunity
; 47(4): 648-663.e8, 2017 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045899
3.
HIV-1 p24 and CD4+ T cell count during boosted protease-inhibitor monotherapy in HIV-infected patients.
Enferm Infecc Microbiol Clin
; 35(3): 174-178, 2017 Mar.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-26976380
4.
Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
Antimicrob Agents Chemother
; 59(6): 3257-62, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25801562
5.
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Clin Infect Dis
; 58(2): 268-73, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24145880
6.
Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.
Clin Infect Dis
; 57(10): 1401-8, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23946224
7.
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Clin Infect Dis
; 56(11): 1646-53, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23429381
8.
Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
Antimicrob Agents Chemother
; 57(8): 3746-51, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23716055
9.
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
J Hepatol
; 56(4): 788-94, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22173157
10.
Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.
J Antimicrob Chemother
; 67(3): 681-4, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22190606
11.
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
J Antimicrob Chemother
; 66(11): 2605-14, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21903660
12.
CD4+ T cell restoration and control of hepatitis C virus replication after childbirth.
J Clin Invest
; 130(2): 748-753, 2020 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31904583
13.
Evolution of the innate and adaptive immune response in women with acute Zika virus infection.
Nat Microbiol
; 5(1): 76-83, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31792427
14.
Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines.
Pathog Immun
; 2(1): 102-125, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28664194
15.
Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
AIDS Res Hum Retroviruses
; 32(1): 6-11, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26414169
16.
Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
Medicine (Baltimore)
; 94(43): e1743, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26512567
17.
Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.
Medicine (Baltimore)
; 94(17): e781, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25929922
18.
Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.
AIDS
; 28(2): 201-8, 2014 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24361681
19.
Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.
Antivir Ther
; 19(5): 443-7, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24434370
20.
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
PLoS One
; 9(7): e101760, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25013899